Dw News
@dwnews·6.3M subscribers·48.6K videos
Why is Germany's CureVac vaccine just 48% effective? | Covid-19 Special
Posted
August 5, 2021
Views
40,924
Likes
500
Comments
211
Engagement
1.74%
August 5, 2021
40,924
500
211
1.74%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
11:52Now PlayingCureVac's COVID-19 jab did not turn out what many hoped it would be. That's despite using the same messenger RNA technology as rivals Moderna and BioNTech-Pfizer. CureVac aimed to produce its vaccine primarily for developing countries – as it can be stored more easily than other products. And despite disappointing trial-results the company is sticking to the plan.
For more news go to
Follow DW on social media:
Für Videos in deutscher Sprache besuchen Sie
#CureVac #Covid19 #coronavirus
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
